Physician profile
Kohlbe Thomas
NPI 1346707908
$1,631.55
in general payments reported to CMS, 2019-2025
27 companies · $652 in 2025
The $652 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $273 · 2024: $706 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.55 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $221.64 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $207.25 | 2024-2025 | Wegovy, Ozempic |
| Pfizer INC. | $112.76 | 2023-2024 | |
| Lilly USA, LLC | $98.66 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $98.21 | 2024-2025 | Nexium, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.13 | 2023-2025 | Relistor, Xifaxan |
| Abbvie INC. | $85.75 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.83 | 2024-2025 | Jardiance |
| Azurity Pharmaceuticals, INC. | $71.62 | 2023-2024 | Horizant, Horizant |
| Exact Sciences Corporation | $70.65 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $66.77 | 2023-2024 | Synchromedii |
| Glaxosmithkline, LLC. | $34.46 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Supernus Pharmaceuticals, INC. | $34.44 | 2025 | Qelbree |
| Scilex Pharmaceuticals INC. | $33.02 | 2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $30.62 | 2023-2024 | Belbuca |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.57 | 2024-2025 | Quviviq, Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $28.40 | 2025 | |
| Viiv Healthcare Company | $28.13 | 2025 | Apretude |
| Amgen INC. | $27.96 | 2024 | Otezla, Repatha |
| Sumitomo Pharma America, INC. | $27.53 | 2025 | Gemtesa |
| Abbott Laboratories | $25.50 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $25.02 | 2024 | Veozah |
| Ibsa Pharma INC. | $24.47 | 2024 | Tirosint, Licart |
| Inspire Medical Systems, INC. | $23.46 | 2024 | Inspire |
| Seqirus USA INC | $20.63 | 2025 | Flucelvax |
| Dexcom, INC. | $20.19 | 2024 | Dexcom G6 Transmitter |
| Impel Pharmaceuticals INC. | $16.88 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kohlbe Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.